BackEuropean Biotech Acquisition Overview

European Biotech Acquisition Long Term Debt

Track European Biotech Acquisition's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

European Biotech Acquisition Long Term Debt History

Loading

European Biotech Acquisition vs. peers: Long Term Debt Comparison

Loading

European Biotech Acquisition Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

European Biotech Acquisition (EBAC) FAQ

The latest long-term debt for EBAC is $0 as of December 2022. In the prior-year period, the figure was $0. Investors often review this figure alongside European Biotech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, EBAC's long-term debt moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in European Biotech Acquisition's operating scale or balance-sheet position.

A long-term debt figure of $0 for EBAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EBAC's long-term debt ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.